hydroxyurea and Asthma studies

Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).

Research Excerpts

Excerpt	Relevance	Reference
"In a non-randomized, non-placebo, single-blind, fixed sequence, pilot study, we evaluated 22 non-smoking, stable, moderate-severe adult asthmatics on maintenance inhaled fluticasone 250 microg/salmeterol 50 microg (F/S) via MDI bid> or =1 yr, with add-on oral zileuton 600 mg qid."	9.14	Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg. ( Gelb, AF; Shinar, C; Simmons, M; Taylor, CF, 2009)
"To assess the therapeutic effects of oral zileuton tablets combined with low-dose beclomethasone compared to doubling the dose of beclomethasone, in improving lung function and reducing asthma symptoms."	9.12	Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. ( Balter, M; Boulet, LP; Cairns, CB; Löfdahl, CG; O'Connor, BJ; Szczeklik, A, 2007)
"This study was conducted to assess the safety and efficacy of zileuton controlled release [CR] 1,200 mg BID added to usual care (UC) in 926 patients with moderate asthma (619 patients randomized to zileuton CR and 307 to placebo)."	9.12	The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. ( Busse, W; Calhoun, W; Dube, L; Harris, J; Panettieri, R; Peters-Golden, M; Russell, H; Walton-Bowen, K; Wenzel, S, 2007)
"Patients with moderate asthma treated with short-acting beta-agonists only were randomized to receive zileuton CR, 1,200 mg twice daily (n = 206); placebo CR, twice daily (n = 203); zileuton immediate-release (IR), 600 mg 4 times daily (n = 101); or placebo IR, 4 times daily (n = 103), for 12 weeks."	9.12	Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. ( Berger, W; Casale, T; Corren, J; Dube, L; Kemp, J; LaVallee, N; Nelson, H; Stepanians, M; Walton-Bowen, K, 2007)
"Zileuton is a 5-lipoxygenase inhibitor approved by the US FDA in 1996 for the treatment of asthma in adults and children."	9.12	Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. ( Cameron, CM; Dube, LM; Kasten, LE; Walton-Bowen, K; Watkins, PB, 2007)
" Since Zileuton, also an inhibitor of 5-LOX, attenuates asthma but with an undesirable side effect, we investigated whether dietary GLA would suppress biosynthesis of PMN-LTB4 isolated from asthma patients and attenuate asthma."	9.11	Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma. ( Gershwin, ME; Morrissey, BM; Naguwa, S; Vang, K; Watnik, M; Wineinger, J; Ziboh, VA, 2004)
"The objective of this study was to determine the effects of allergen exposure on leukotriene generation and inflammation within the airways of allergic asthmatics and evaluate the effects of the 5-lipoxygenase inhibitor zileuton on these responses."	9.09	Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. ( Bleecker, ER; Dubé, LM; Hasday, JD; Hebel, JR; Lanni, C; Meltzer, SS; Moore, WC; Wisniewski, P, 2000)
"From bronchoprovocation studies and investigations of the acute effects of drugs that inhibit leukotrienes (LT), the hypothesis has emerged that leukotrienes are important mediators of airway obstruction and other symptoms in aspirin-intolerant asthma (AIA)."	9.08	Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. ( Bochenek, G; Boodhoo, TI; Dahlén, B; Dahlén, SE; Dubé, LM; Kumlin, M; Mastalerz, L; Nizankowska, E; Pinis, G; Swanson, LJ; Szczeklik, A; Wright, S; Zetterström, O, 1998)
"Zileuton, a leukotriene pathway inhibitor used to treat asthma, improves lung function, relieves symptoms, and is well tolerated."	9.08	Safety and clinical efficacy of zileuton in patients with chronic asthma. ( Carpentier, PJ; Dubé, LM; Kemp, JP; Lancaster, JF; Lazarus, SC; Lee, T; Ochs, RF; Wenzel, S, 1998)
"The aim of the study was to determine whether zileuton, an inhibitor of 5-lipoxygenase, attenuated bronchial hyperresponsiveness (BHR) in asthmatic subjects who had marked BHR during maintenance treatment with inhaled corticosteroids (ICS)."	9.08	Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids. ( Bootsma, GP; Dekhuijzen, PN; Festen, J; van den Berg, LR; van Herwaarden, CL; Wielders, PL, 1997)
"Zileuton, a leukotriene pathway inhibitor, was compared with slowly absorbed theophylline in a randomized, double-blind study of patients with chronic asthma."	9.08	A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group. ( Dubé, LM; Lancaster, JF; Petty, T; Schwartz, HJ; Swanson, LJ, 1998)
" In the present study we examined the effect of oral ABT-761, a novel 5-lipoxygenase (5-LO) inhibitor, on exercise- and adenosine (AMP)-induced bronchoconstriction in nine asthmatics."	9.08	The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects. ( Carpentier, PJ; Drajesk, JF; Joos, GF; Kips, JC; Pauwels, RA; Van Schoor, J, 1997)
"Zileuton produces objective and subjective improvements in patients with mild to moderate asthma and is well tolerated."	9.08	Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. ( Dubé, LM; Lancaster, J; Liu, MC, 1996)
"1%) of 132 patients receiving 600 mg of zileuton four times a day required corticosteroid treatment for asthma vs 21 (15."	9.08	Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. ( Cohn, J; Drazen, JM; Dubé, L; Israel, E, 1996)
"To evaluate the effectiveness of inhibiting the formation of the 5-lipoxygenase products of arachidonic acid by the 5-lipoxygenase inhibitor zileuton in the treatment of mild-to-moderate asthma."	9.07	The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. ( Busse, W; Cohn, J; Drazen, JM; Fish, J; Grossman, J; Israel, E; Kaiser, HB; Karahalios, P; Kemp, JP; Lanni, C; Ledford, D; Murray, JJ; Pearlman, H; Pierson, W; Rosenthal, R; Rubin, P; Segal, AT; Siegel, SC; Tinkelman, D; Wenzel, S, 1993)
"The increase in nasal symptoms in aspirin-sensitive patients with asthma after aspirin ingestion is associated with increases in nasal tryptase, histamine, and cysteinyl leukotriene levels."	9.07	Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. ( Callery, JC; Cohn, J; Drazen, JM; Fischer, AR; Igarashi, Y; Kaliner, MA; Lilly, CM; Rosenberg, MA; Rubin, P; White, MV, 1994)
"A subset of persons with asthma develop bronchospasm, naso-ocular, gastrointestinal, and/or dermal reactions after ingesting aspirin (ASA) or agents with the capacity to inhibit cyclooxygenase."	9.07	The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. ( Callery, JC; Cohn, J; Drazen, JM; Fischer, AR; Israel, E; Lilly, CM; Rosenberg, MA; Rubin, P; Shapiro, J, 1993)
"We sought to study our hypothesis that response to zileuton varies across specific asthmatic phenotypes."	7.96	Zileuton use and phenotypic features in asthma. ( Holguin, F; Nouraie, M; Parikh, A; Thalanayar Muthukrishnan, P, 2020)
"Variable responsiveness to zileuton, a leukotriene antagonist used to treat asthma, may be due in part to genetic variation."	7.88	The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma. ( Dahlin, A; Irvin, CG; Kubo, M; Lima, JJ; Litonjua, AA; Peters, SP; Qiu, W; Tamari, M; Tantisira, KG; Weiss, ST; Wu, AC, 2018)
"Leukotriene B4 (LTB4), a potent chemokinetic mediator for neutrophils, is enhanced by interleukin-8 (IL-8) and may play a key role in the inflammatory response of asthma."	7.70	Allergen-stimulated leukotriene B4 and interleukin-8 levels in patients with asthma and allergic rhinitis-modulation by a lipid pathway inhibitor. ( Bouboulis, D; Frieri, M; Lark, G; Sansone, G; Schaefer, PA; Therattil, JM; Wang, SF; Zitt, M, 1998)
" Patients who demonstrate improved asthma control with zileuton 600 mg QID may be able to reduce their daily dosage and/or frequency while still maintaining the same level of symptom control."	6.68	Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. ( Dubé, LM; DuBuske, LM; Grossman, J; Lancaster, JF; Swanson, LJ, 1997)
"Treatment with Zileuton for 2 weeks significantly increased thromboxane B(2) levels from baseline levels of 267 +/- 54 microg/l to 389 +/- 62 microg/l after 2 weeks of treatment (P < 0."	5.32	Zileuton, a 5-lipoxygenase inhibitor, increases production of thromboxane A2 and platelet aggregation in patients with asthma. ( Dev, A; Leong, AB; Wu, X, 2003)
"Aspirin sensitivity was established previously in all six patients during a prior ASA oral challenge."	5.31	Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. ( Daffern, PJ; Pauls, JD; Simon, RA; Stevenson, DD, 2000)
"In a non-randomized, non-placebo, single-blind, fixed sequence, pilot study, we evaluated 22 non-smoking, stable, moderate-severe adult asthmatics on maintenance inhaled fluticasone 250 microg/salmeterol 50 microg (F/S) via MDI bid> or =1 yr, with add-on oral zileuton 600 mg qid."	5.14	Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg. ( Gelb, AF; Shinar, C; Simmons, M; Taylor, CF, 2009)
"To assess the therapeutic effects of oral zileuton tablets combined with low-dose beclomethasone compared to doubling the dose of beclomethasone, in improving lung function and reducing asthma symptoms."	5.12	Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. ( Balter, M; Boulet, LP; Cairns, CB; Löfdahl, CG; O'Connor, BJ; Szczeklik, A, 2007)
"To evaluate whether controller medications, particularly leukotriene modifier drugs, taken during oral aspirin challenges can reduce the risk of severe asthmatic responses."	5.12	Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. ( Ludington, E; Mehra, P; Simon, RA; Stevenson, DD; White, A, 2006)
"This study was conducted to assess the safety and efficacy of zileuton controlled release [CR] 1,200 mg BID added to usual care (UC) in 926 patients with moderate asthma (619 patients randomized to zileuton CR and 307 to placebo)."	5.12	The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. ( Busse, W; Calhoun, W; Dube, L; Harris, J; Panettieri, R; Peters-Golden, M; Russell, H; Walton-Bowen, K; Wenzel, S, 2007)
"Patients with moderate asthma treated with short-acting beta-agonists only were randomized to receive zileuton CR, 1,200 mg twice daily (n = 206); placebo CR, twice daily (n = 203); zileuton immediate-release (IR), 600 mg 4 times daily (n = 101); or placebo IR, 4 times daily (n = 103), for 12 weeks."	5.12	Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. ( Berger, W; Casale, T; Corren, J; Dube, L; Kemp, J; LaVallee, N; Nelson, H; Stepanians, M; Walton-Bowen, K, 2007)
"Zileuton is a 5-lipoxygenase inhibitor approved by the US FDA in 1996 for the treatment of asthma in adults and children."	5.12	Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. ( Cameron, CM; Dube, LM; Kasten, LE; Walton-Bowen, K; Watkins, PB, 2007)
" Since Zileuton, also an inhibitor of 5-LOX, attenuates asthma but with an undesirable side effect, we investigated whether dietary GLA would suppress biosynthesis of PMN-LTB4 isolated from asthma patients and attenuate asthma."	5.11	Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma. ( Gershwin, ME; Morrissey, BM; Naguwa, S; Vang, K; Watnik, M; Wineinger, J; Ziboh, VA, 2004)
"The objective of this study was to determine the effects of allergen exposure on leukotriene generation and inflammation within the airways of allergic asthmatics and evaluate the effects of the 5-lipoxygenase inhibitor zileuton on these responses."	5.09	Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. ( Bleecker, ER; Dubé, LM; Hasday, JD; Hebel, JR; Lanni, C; Meltzer, SS; Moore, WC; Wisniewski, P, 2000)
"Zileuton, a leukotriene pathway inhibitor, was compared with slowly absorbed theophylline in a randomized, double-blind study of patients with chronic asthma."	5.08	A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group. ( Dubé, LM; Lancaster, JF; Petty, T; Schwartz, HJ; Swanson, LJ, 1998)
"The aim of the study was to determine whether zileuton, an inhibitor of 5-lipoxygenase, attenuated bronchial hyperresponsiveness (BHR) in asthmatic subjects who had marked BHR during maintenance treatment with inhaled corticosteroids (ICS)."	5.08	Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids. ( Bootsma, GP; Dekhuijzen, PN; Festen, J; van den Berg, LR; van Herwaarden, CL; Wielders, PL, 1997)
"From bronchoprovocation studies and investigations of the acute effects of drugs that inhibit leukotrienes (LT), the hypothesis has emerged that leukotrienes are important mediators of airway obstruction and other symptoms in aspirin-intolerant asthma (AIA)."	5.08	Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. ( Bochenek, G; Boodhoo, TI; Dahlén, B; Dahlén, SE; Dubé, LM; Kumlin, M; Mastalerz, L; Nizankowska, E; Pinis, G; Swanson, LJ; Szczeklik, A; Wright, S; Zetterström, O, 1998)
" We investigated the effects of zileuton, an inhibitor of 5-lipoxygenase (5-LO), on airway responsiveness to cold, dry air in patients with moderate asthma."	5.08	Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. ( Awni, WM; Cohn, J; Drazen, JM; Fischer, AR; Frantz, R; Israel, E; McFadden, CA, 1995)
"Zileuton, a leukotriene pathway inhibitor used to treat asthma, improves lung function, relieves symptoms, and is well tolerated."	5.08	Safety and clinical efficacy of zileuton in patients with chronic asthma. ( Carpentier, PJ; Dubé, LM; Kemp, JP; Lancaster, JF; Lazarus, SC; Lee, T; Ochs, RF; Wenzel, S, 1998)
" In the present study we examined the effect of oral ABT-761, a novel 5-lipoxygenase (5-LO) inhibitor, on exercise- and adenosine (AMP)-induced bronchoconstriction in nine asthmatics."	5.08	The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects. ( Carpentier, PJ; Drajesk, JF; Joos, GF; Kips, JC; Pauwels, RA; Van Schoor, J, 1997)
"1%) of 132 patients receiving 600 mg of zileuton four times a day required corticosteroid treatment for asthma vs 21 (15."	5.08	Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. ( Cohn, J; Drazen, JM; Dubé, L; Israel, E, 1996)
"Zileuton produces objective and subjective improvements in patients with mild to moderate asthma and is well tolerated."	5.08	Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. ( Dubé, LM; Lancaster, J; Liu, MC, 1996)
"To evaluate the effectiveness of inhibiting the formation of the 5-lipoxygenase products of arachidonic acid by the 5-lipoxygenase inhibitor zileuton in the treatment of mild-to-moderate asthma."	5.07	The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. ( Busse, W; Cohn, J; Drazen, JM; Fish, J; Grossman, J; Israel, E; Kaiser, HB; Karahalios, P; Kemp, JP; Lanni, C; Ledford, D; Murray, JJ; Pearlman, H; Pierson, W; Rosenthal, R; Rubin, P; Segal, AT; Siegel, SC; Tinkelman, D; Wenzel, S, 1993)
"A subset of persons with asthma develop bronchospasm, naso-ocular, gastrointestinal, and/or dermal reactions after ingesting aspirin (ASA) or agents with the capacity to inhibit cyclooxygenase."	5.07	The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. ( Callery, JC; Cohn, J; Drazen, JM; Fischer, AR; Israel, E; Lilly, CM; Rosenberg, MA; Rubin, P; Shapiro, J, 1993)
"The increase in nasal symptoms in aspirin-sensitive patients with asthma after aspirin ingestion is associated with increases in nasal tryptase, histamine, and cysteinyl leukotriene levels."	5.07	Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. ( Callery, JC; Cohn, J; Drazen, JM; Fischer, AR; Igarashi, Y; Kaliner, MA; Lilly, CM; Rosenberg, MA; Rubin, P; White, MV, 1994)
"The effect of a single oral dose (800 mg) of zileuton (A-64077), a specific 5-lipoxygenase inhibitor, on the early and late airway responses to inhaled allergen was studied in a randomised, double blind, placebo controlled, and crossover trial in nine subjects with atopic asthma."	5.07	Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. ( Barnes, NC; Barnes, PJ; Hui, KP; Kesterson, J; Rubin, P; Taylor, GW; Taylor, IK, 1991)
"The three leukotriene (LT) modifiers approved for use in the United States, zileuton, zafirlukast, and montelukast, are the first new class of therapeutic agents to be introduced in 20 years for the treatment of asthma."	4.80	New treatments for asthma: the role of leukotriene modifier agents. ( Valacer, DJ, 1999)
"We sought to study our hypothesis that response to zileuton varies across specific asthmatic phenotypes."	3.96	Zileuton use and phenotypic features in asthma. ( Holguin, F; Nouraie, M; Parikh, A; Thalanayar Muthukrishnan, P, 2020)
"Variable responsiveness to zileuton, a leukotriene antagonist used to treat asthma, may be due in part to genetic variation."	3.88	The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma. ( Dahlin, A; Irvin, CG; Kubo, M; Lima, JJ; Litonjua, AA; Peters, SP; Qiu, W; Tamari, M; Tantisira, KG; Weiss, ST; Wu, AC, 2018)
"This article presents information on the safety of zafirlukast, montelukast, and zileuton, three antileukotrienes (anti-LTs) approved in the United States for the prophylaxis and treatment of asthma."	3.71	Safety of antileukotriene agents in asthma management. ( Spector, SL, 2001)
"Leukotriene B4 (LTB4), a potent chemokinetic mediator for neutrophils, is enhanced by interleukin-8 (IL-8) and may play a key role in the inflammatory response of asthma."	3.70	Allergen-stimulated leukotriene B4 and interleukin-8 levels in patients with asthma and allergic rhinitis-modulation by a lipid pathway inhibitor. ( Bouboulis, D; Frieri, M; Lark, G; Sansone, G; Schaefer, PA; Therattil, JM; Wang, SF; Zitt, M, 1998)
" Patients who demonstrate improved asthma control with zileuton 600 mg QID may be able to reduce their daily dosage and/or frequency while still maintaining the same level of symptom control."	2.68	Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. ( Dubé, LM; DuBuske, LM; Grossman, J; Lancaster, JF; Swanson, LJ, 1997)
" dosing and an intravenous preparation for acute asthma exacerbations may enhance clinical utility and expand therapeutic indications."	2.44	Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. ( Berger, W; Cairns, CB; De Chandt, MT, 2007)
"The use of leukotriene inhibitors in treating atopic dermatitis, aspirin-intolerant asthma, and chronic idiopathic urticaria appears promising but has not been studied thoroughly."	2.44	Leukotriene inhibitors in the treatment of allergy and asthma. ( Dickerson, KS; Luttermoser, GK; Scow, DT, 2007)
"As bronchial asthma is thought to be provoked by a variety of causes, therapeutic drug should be selected according to the state of the disease."	2.39	[5-lipoxygenase inhibitors in asthma therapy]. ( Tanaka, R, 1996)
" Conversely, DO mice lacking adverse liver pathology following zileuton exposure experienced decreased hepatic concentrations of resistin and increased concentrations of insulin and leptin, providing potential clues into mechanisms of toxicity resistance."	1.56	Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice. ( Bell, N; Gatti, DM; Harrill, AH; James, LP; Larson, GJ; Lyn-Cook, LE; Mattes, WB; Mayeux, PR; You, D, 2020)
"Treatment with Zileuton for 2 weeks significantly increased thromboxane B(2) levels from baseline levels of 267 +/- 54 microg/l to 389 +/- 62 microg/l after 2 weeks of treatment (P < 0."	1.32	Zileuton, a 5-lipoxygenase inhibitor, increases production of thromboxane A2 and platelet aggregation in patients with asthma. ( Dev, A; Leong, AB; Wu, X, 2003)
"Aspirin sensitivity was established previously in all six patients during a prior ASA oral challenge."	1.31	Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. ( Daffern, PJ; Pauls, JD; Simon, RA; Stevenson, DD, 2000)
" ABT-761 has shown excellent oral bioavailability and an extended duration of plasma levels in man, and initial results for a single 200 mg po dose have shown a significant protective effect against exercise- and adenosine-induced bronchoconstriction in asthmatics [215839]."	1.31	ABT-761 (Abbott). ( Reid, JJ, 2001)
" Therefore, in this study, we determined if multiple dosing with zileuton, which theoretically could improve tissue levels, would provide protection against the antigen-induced EAR as well as the LAR."	1.30	The effects of multiple dosing with zileuton on antigen-induced responses in sheep. ( Abraham, WM; Allegra, L; Scuri, M, 1998)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.16)	18.7374
1990's	43 (50.00)	18.2507
2000's	32 (37.21)	29.6817
2010's	7 (8.14)	24.3611
2020's	3 (3.49)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Evaluation of Additive Effects of Zileuton to Advair on Total Exhaled, Bronchial, and Alveolar Nitric Oxide in Asthmatics[NCT00575861]	Phase 4	19 participants (Actual)	Interventional	2005-09-30	Completed
[NCT00005564]		0 participants	Observational	1997-07-31	Completed
Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough：A Prospective, Open Label, Randomized and Placebo-Controlled Trial[NCT02655562]	Phase 4	200 participants (Anticipated)	Interventional	2016-04-30	Suspended (stopped due to There are difficulties in recruiting patients)
Predicting the Bronchoprotective Response to a Leukotriene Modifier by Genetic Polymorphism[NCT00116324]	Phase 3	150 participants	Interventional	2003-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
[What helps for persistent symptoms of asthma during inhalative steroid therapy?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:42 Topics: Acetates; Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists;	2011
New treatments for asthma: the role of leukotriene modifier agents. Journal of the National Medical Association, 1999, Volume: 91, Issue:8 Suppl Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Asthma, Exercise-I	1999
[Anti-leukotrienes in allergic diseases in children]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2003, Volume: 14, Issue:84 Topics: Acetates; Asthma; Child; Cyclopropanes; Humans; Hydroxyurea; Leukotriene Antagonists; Leukotrienes;	2003
Recent advances in the management of asthma using leukotriene modifiers. American journal of respiratory medicine : drugs, devices, and other interventions, 2003, Volume: 2, Issue:2 Topics: Acetates; Administration, Inhalation; Adolescent; Adult; Asthma; Child; Child, Preschool; Chromones;	2003
Leukotrienes antagonists in the management of bronchial asthma. Romanian journal of internal medicine = Revue roumaine de medecine interne, 2003, Volume: 41, Issue:1 Topics: Asthma; Humans; Hydroxyurea; Leukotriene Antagonists; Leukotrienes	2003
Treatment of asthma with antileukotrienes: first line or last resort therapy? European journal of pharmacology, 2006, Mar-08, Volume: 533, Issue:1-3 Topics: Acetates; Animals; Asthma; Clinical Trials as Topic; Cyclopropanes; Humans; Hydroxyurea; Leukotriene	2006
Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Medicinal research reviews, 2007, Volume: 27, Issue:4 Topics: Adult; Animals; Asthma; Cardiovascular Diseases; Child; Child, Preschool; Dermatitis, Atopic; Female	2007
Leukotriene inhibitors in the treatment of allergy and asthma. American family physician, 2007, Jan-01, Volume: 75, Issue:1 Topics: Acetates; Anti-Asthmatic Agents; Asthma; Asthma, Exercise-Induced; Cyclopropanes; Dermatitis, Atopic	2007
Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. International journal of clinical practice, 2007, Volume: 61, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma; Dermatitis, Atopic; Drug Administration Schedule; H	2007
Inflammation and airway reactivity. Experimental lung research, 1984, Volume: 6, Issue:2 Topics: Aerosols; Animals; Asthma; Disease Models, Animal; Dogs; Endotoxins; Granulocytes; Guinea Pigs; Hist	1984
[Allergy and leukotrienes]. Klinicheskaia meditsina, 1995, Volume: 73, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Asthma; Derm	1995
Leukotriene antagonists and inhibitors: clinical applications. Advances in prostaglandin, thromboxane, and leukotriene research, 1995, Volume: 23 Topics: Animals; Asthma; Glomerulonephritis; Humans; Hydroxyurea; Indoles; Inflammatory Bowel Diseases; Leuk	1995
Zileuton. Lancet (London, England), 1996, Aug-24, Volume: 348, Issue:9026 Topics: Arthritis, Rheumatoid; Asthma; Humans; Hydroxyurea; Lipoxygenase Inhibitors	1996
Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents. Archives of internal medicine, 1996, Oct-28, Volume: 156, Issue:19 Topics: Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Humans; Hydroxyurea	1996
[5-lipoxygenase inhibitors in asthma therapy]. Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:11 Topics: Arachidonate 5-Lipoxygenase; Arachidonic Acids; Asthma; Humans; Hydroxyurea; Lipoxygenase Inhibitors	1996
Antileukotriene therapy for asthma. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996, Dec-01, Volume: 53, Issue:23 Topics: Asthma; Humans; Hydroxyurea; Inflammation; Leukotrienes; Lipoxygenase Inhibitors	1996
Antileukotriene agents. Current opinion in pulmonary medicine, 1997, Volume: 3, Issue:3 Topics: Anti-Asthmatic Agents; Asthma; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes;	1997
New directions in asthma drug therapy. Hospital practice (1995), 1998, Feb-15, Volume: 33, Issue:2 Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Chromones; Humans; Hydroxyur	1998
The role of antileukotrienes in asthma management. Current opinion in pulmonary medicine, 1998, Volume: 4, Issue:1 Topics: Acetates; Animals; Anti-Asthmatic Agents; Asthma; Chromones; Cyclopropanes; Humans; Hydroxyurea; Ind	1998
New approaches to anti-inflammatory therapy for asthma. The American journal of medicine, 1998, Volume: 104, Issue:3 Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Di	1998
The role of leukotriene modifiers in the treatment of asthma. American journal of respiratory and critical care medicine, 1998, Volume: 157, Issue:5 Pt 1 Topics: Animals; Asthma; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes; Lipoxygenase I	1998
Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. American journal of respiratory and critical care medicine, 1998, Volume: 157, Issue:6 Pt 2 Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Humans; Hydroxyurea; Indoles	1998
[Potential importance of antileukotrienes in the treatment of asthma and other inflammatory diseases: apropos of a new pharmacological class]. La Revue de medecine interne, 1998, Volume: 19, Issue:2 Topics: Acetophenones; Adult; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthr	1998
Leukotriene antagonism in asthma and rhinitis. Respiratory medicine, 1998, Volume: 92, Issue:6 Topics: Acetates; Asthma; Bronchi; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leu	1998
[The role of leukotrienes in inflammation and leukotriene inhibitors]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 1999, Volume: 7, Issue:39 Topics: Acetates; Arachidonate 5-Lipoxygenase; Asthma; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotri	1999
Leukotriene modifiers in pediatric asthma management. Pediatrics, 2001, Volume: 107, Issue:2 Topics: Acetates; Adrenal Cortex Hormones; Anti-Asthmatic Agents; Asthma; Child; Cyclopropanes; Humans; Hydr	2001
Leukotriene inhibitors and non-steroidal therapies in the treatment of asthma. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:1 Topics: Acetates; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Asthma; Bronchocon	2001
Antileukotrienes in asthma: present situation. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:3 Topics: Acetates; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Chromones; Clinical Trials as Topic;	2001
[Leukotriene modifiers]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:10 Topics: Acetates; Asthma; Chromones; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; L	2001
Leukotriene modifiers. Expanded role may be on horizon. Advance for nurse practitioners, 2000, Volume: 8, Issue:10 Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Cyclopropanes; Drug Interactions;	2000

Article	Year
Genome-wide association study of leukotriene modifier response in asthma. The pharmacogenomics journal, 2016, Volume: 16, Issue:2 Topics: Acetates; Anti-Asthmatic Agents; Asthma; Cohort Studies; Cyclopropanes; Gene-Environment Interaction	2016
5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenetics and genomics, 2009, Volume: 19, Issue:3 Topics: Acetates; Adult; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Cysteine; Female; Forced Expiratory V	2009
Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg. Pulmonary pharmacology & therapeutics, 2009, Volume: 22, Issue:6 Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; As	2009
Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma. Clinical & developmental immunology, 2004, Volume: 11, Issue:1 Topics: Adult; Aged; Arthritis, Rheumatoid; Asthma; Dietary Supplements; Double-Blind Method; Fatty Acids; F	2004
Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 97, Issue:5 Topics: Acetates; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Asthmatic Agents; Aspirin; Asthma;	2006
Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. Respiratory medicine, 2007, Volume: 101, Issue:6 Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bec	2007
The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. The Journal of asthma : official journal of the Association for the Care of Asthma, 2007, Volume: 44, Issue:4 Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Asthma; Child; Delayed-Action	2007
Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2007, Volume: 99, Issue:2 Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-	2007
Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug safety, 2007, Volume: 30, Issue:9 Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Asthma; Chemical and Drug Induced Liver In	2007
Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. American journal of respiratory and critical care medicine, 1995, Volume: 152, Issue:4 Pt 1 Topics: Adult; Arachidonate 5-Lipoxygenase; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests;	1995
Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. American journal of respiratory and critical care medicine, 1995, Volume: 152, Issue:3 Topics: Adolescent; Adult; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Bronchoconstri	1995
Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. The Journal of allergy and clinical immunology, 1994, Volume: 94, Issue:6 Pt 1 Topics: Adult; Aspirin; Asthma; Blood Proteins; Chymases; Cross-Over Studies; Double-Blind Method; Eosinophi	1994
The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Annals of internal medicine, 1993, Dec-01, Volume: 119, Issue:11 Topics: Adult; Albuterol; Asthma; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory	1993
The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. The American review of respiratory disease, 1993, Volume: 148, Issue:6 Pt 1 Topics: Adult; Arachidonate 5-Lipoxygenase; Aspirin; Asthma; Bronchoconstriction; Double-Blind Method; Drug	1993
Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA, 1996, Mar-27, Volume: 275, Issue:12 Topics: Adrenergic beta-Agonists; Adult; Analysis of Variance; Asthma; Double-Blind Method; Drug Administrat	1996
Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. The Journal of allergy and clinical immunology, 1996, Volume: 98, Issue:5 Pt 1 Topics: Adolescent; Adrenergic beta-Agonists; Adult; Anti-Asthmatic Agents; Asthma; Bronchoconstriction; Dou	1996
The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects. American journal of respiratory and critical care medicine, 1997, Volume: 155, Issue:3 Topics: Adenosine; Adult; Asthma; Bronchi; Bronchial Provocation Tests; Bronchoconstriction; Cross-Over Stud	1997
A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group. Archives of internal medicine, 1998, Jan-26, Volume: 158, Issue:2 Topics: Adult; Asthma; Bronchodilator Agents; Double-Blind Method; Female; Forced Expiratory Volume; Humans;	1998
Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids. The European respiratory journal, 1997, Volume: 10, Issue:12 Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Asthma; Bronchial Hyperreactivity; Bronc	1997
Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. American journal of respiratory and critical care medicine, 1998, Volume: 157, Issue:4 Pt 1 Topics: Adrenergic beta-Agonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Hyperr	1998
The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma. American journal of respiratory and critical care medicine, 1998, Volume: 157, Issue:5 Pt 1 Topics: Adult; Airway Resistance; Asthma; Cross-Over Studies; Double-Blind Method; Female; Humans; Hydroxyur	1998
Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. The American journal of managed care, 1997, Volume: 3, Issue:4 Topics: Adolescent; Adult; Aged; Asthma; Double-Blind Method; Drug Administration Schedule; Humans; Hydroxyu	1997
Safety and clinical efficacy of zileuton in patients with chronic asthma. The American journal of managed care, 1998, Volume: 4, Issue:6 Topics: Asthma; Chronic Disease; Disease Management; Forced Expiratory Volume; Humans; Hydroxyurea; Lipoxyge	1998
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature genetics, 1999, Volume: 22, Issue:2 Topics: Alleles; Anti-Asthmatic Agents; Arachidonate 5-Lipoxygenase; Asthma; Gene Frequency; Genetic Variati	1999
Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. American journal of respiratory and critical care medicine, 2000, Volume: 161, Issue:4 Pt 1 Topics: Adult; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Cytokines; Double-Blind Me	2000
Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax, 1991, Volume: 46, Issue:3 Topics: Adult; Allergens; Asthma; Double-Blind Method; Forced Expiratory Volume; Humans; Hydroxyurea; Leukot	1991
The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. The New England journal of medicine, 1990, Dec-20, Volume: 323, Issue:25 Topics: Asthma; Bronchial Provocation Tests; Bronchoconstriction; Calcimycin; Cold Temperature; Double-Blind	1990

Article	Year
Screening for asthma in preschool children with sickle cell disease. The Journal of asthma : official journal of the Association for the Care of Asthma, 2023, Volume: 60, Issue:9 Topics: Aged; Anemia, Sickle Cell; Asthma; Child, Preschool; Dermatitis, Atopic; Humans; Hydroxyurea; Prospe	2023
Zileuton use and phenotypic features in asthma. Pulmonary pharmacology & therapeutics, 2020, Volume: 60 Topics: Adult; Aged; Anti-Asthmatic Agents; Asthma; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Lu	2020
Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice. Toxicological sciences : an official journal of the Society of Toxicology, 2020, 06-01, Volume: 175, Issue:2 Topics: Animals; Anti-Asthmatic Agents; Asthma; Chemical and Drug Induced Liver Injury; Collaborative Cross	2020
38-Year-Old Man With Asthma and Eosinophilia. Mayo Clinic proceedings, 2017, Volume: 92, Issue:8 Topics: Adult; Anti-Asthmatic Agents; Antineoplastic Agents; Asthma; Diagnosis, Differential; Disease Progre	2017
The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma. The pharmacogenomics journal, 2018, Volume: 18, Issue:5 Topics: Asthma; Cell Line; Humans; Hydroxyurea; Leukotrienes; Phosphatidylinositol 3-Kinases; Polymorphism,	2018
Airway remodeling in asthma: tumor of the airway? Respiration; international review of thoracic diseases, 2013, Volume: 86, Issue:5 Topics: Airway Remodeling; Allergens; Animals; Asthma; Hydroxyurea; Leukotriene Antagonists; Lung; Male	2013
Effects of zileuton on airway smooth muscle remodeling after repeated allergen challenge in brown Norway rats. Respiration; international review of thoracic diseases, 2013, Volume: 86, Issue:5 Topics: Airway Remodeling; Allergens; Animals; Asthma; Bronchoalveolar Lavage Fluid; Drug Evaluation, Precli	2013
Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13. The Journal of clinical investigation, 2016, Volume: 126, Issue:2 Topics: Anemia, Sickle Cell; Animals; Asthma; Disease Models, Animal; Hydroxyurea; Interleukin-13; Leukotrie	2016
Zileuton, a 5-lipoxygenase inhibitor, increases production of thromboxane A2 and platelet aggregation in patients with asthma. American journal of hematology, 2003, Volume: 74, Issue:1 Topics: Adult; Aged; Asthma; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Middle Aged; Platel	2003
Leukotriene modifier use and asthma severity: how is a new medication being used by adults with asthma? Archives of internal medicine, 2004, Mar-22, Volume: 164, Issue:6 Topics: Acetates; Adult; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Female; Health Status Indicators; Hos	2004
WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity. European journal of pharmacology, 1993, May-19, Volume: 236, Issue:2 Topics: Administration, Oral; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Asthma; Female; Guinea	1993
Zileuton for asthma. The Medical letter on drugs and therapeutics, 1997, Feb-28, Volume: 39, Issue:995 Topics: Adolescent; Adult; Asthma; Child; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Dr	1997
Allergen-stimulated leukotriene B4 and interleukin-8 levels in patients with asthma and allergic rhinitis-modulation by a lipid pathway inhibitor. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1998, Volume: 81, Issue:4 Topics: Adult; Aged; Allergens; Asthma; Female; Humans; Hydroxyurea; Interleukin-8; Leukocytes, Mononuclear;	1998
Drugs for asthma. The Medical letter on drugs and therapeutics, 1999, Jan-15, Volume: 41, Issue:1044 Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adr	1999
The effects of multiple dosing with zileuton on antigen-induced responses in sheep. Pulmonary pharmacology & therapeutics, 1998, Volume: 11, Issue:4 Topics: Airway Resistance; Animals; Asthma; Bronchial Provocation Tests; Disease Models, Animal; Drug Admini	1998
Drugs for asthma. The Medical letter on drugs and therapeutics, 2000, Mar-06, Volume: 42, Issue:1073 Topics: Acetates; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta	2000
The use of newer asthma and allergy medications during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2000, Volume: 84, Issue:5 Topics: Abnormalities, Drug-Induced; Acetates; Administration, Inhalation; Administration, Intranasal; Admin	2000
Recurrent panniculitis in a man with asthma receiving treatment with leukotriene-modifying agents. Mayo Clinic proceedings, 2000, Volume: 75, Issue:6 Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Cyclopropanes; Dia	2000
Antileukotriene agents and aspirin-sensitive asthma: are we removing the second bassoonist or skating to where the puck is gonna be? Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2000, Volume: 85, Issue:1 Topics: Aspirin; Asthma; Bronchial Spasm; Humans; Hydroxyurea; Leukotriene Antagonists; Therapeutic Equivale	2000
Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2000, Volume: 85, Issue:1 Topics: Administration, Oral; Aspirin; Asthma; Desensitization, Immunologic; Humans; Hydroxyurea; Leukotrien	2000
Clinical predictors of health-related quality of life depend on asthma severity. American journal of respiratory and critical care medicine, 2001, Volume: 163, Issue:4 Topics: Adult; Albuterol; Analysis of Variance; Asthma; Female; Follow-Up Studies; Humans; Hydroxyurea; Male	2001
[Eosinophilic ascites as a presenting symptom of the hypereosinophilic syndrome]. Harefuah, 2001, Volume: 140, Issue:6 Topics: Adult; Ascitic Fluid; Asthma; Diagnosis, Differential; Eosinophilia; Humans; Hydroxyurea; Hypereosin	2001
Safety of antileukotriene agents in asthma management. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2001, Volume: 86, Issue:6 Suppl 1 Topics: Acetates; Asthma; Churg-Strauss Syndrome; Clinical Trials as Topic; Cyclopropanes; Humans; Hydroxyur	2001
ABT-761 (Abbott). Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:1 Topics: Asthma; Clinical Trials, Phase III as Topic; Humans; Hydroxyurea; Lipoxygenase Inhibitors	2001
The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep. European journal of pharmacology, 1992, Jul-07, Volume: 217, Issue:2-3 Topics: Administration, Oral; Animals; Antigens; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage F	1992
Therapeutic approaches to reduce airway inflammation. Agents and actions. Supplements, 1991, Volume: 35 Topics: Animals; Anti-Inflammatory Agents; Asthma; Blood Platelets; Bronchi; Cell Adhesion Molecules; Humans	1991
Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma. Agents and actions. Supplements, 1991, Volume: 34 Topics: Anaphylaxis; Animals; Asthma; Benzeneacetamides; Bronchial Diseases; Guinea Pigs; Humans; Hydroxamic	1991
Asthma: the molecular light at the end of the tracheal tunnel. Hospital practice (Office ed.), 1991, Feb-15, Volume: 26, Issue:2 Topics: Asthma; Humans; Hydroxyeicosatetraenoic Acids; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; P	1991
From the National Institutes of Health. JAMA, 1991, Mar-06, Volume: 265, Issue:9 Topics: Arthritis, Juvenile; Asthma; CD4 Antigens; Cells, Cultured; Exotoxins; HIV-1; HLA Antigens; Humans;	1991

hydroxyurea and Asthma

Research Excerpts

Research

Studies (86)

Authors

Clinical Trials (4)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Chan, KH	1
Stark, JM	1
Mosquera, RA	1
Brown, DL	1
Menon, N	1
Nguyen, TT	1
Yadav, A	1
Thalanayar Muthukrishnan, P	1
Nouraie, M	1
Parikh, A	1
Holguin, F	1
You, D	1
Lyn-Cook, LE	1
Gatti, DM	1
Bell, N	1
Mayeux, PR	1
James, LP	1
Mattes, WB	1
Larson, GJ	1
Harrill, AH	1
Andersen, C	1
Yadav, H	1
Iyer, VN	1
Dahlin, A	2
Qiu, W	1
Litonjua, AA	1
Lima, JJ	2
Tamari, M	2
Kubo, M	2
Irvin, CG	2
Peters, SP	2
Wu, AC	1
Weiss, ST	3
Tantisira, KG	3
Seow, CY	1
van Eeden, S	1
Chen, WJ	1
Liaw, SF	1
Lin, CC	1
Lin, MW	1
Chang, FT	1
Litonjua, A	1
Eiymo Mwa Mpollo, MS	1
Brandt, EB	1
Shanmukhappa, SK	1
Arumugam, PI	1
Tiwari, S	1
Loberg, A	1
Pillis, D	1
Rizvi, T	1
Lindsey, M	1
Jonck, B	1
Carmeliet, P	1
Kalra, VK	1
Le Cras, TD	1
Ratner, N	1
Wills-Karp, M	1
Hershey, GK	1
Malik, P	1
Lima, J	1
Sylvia, J	1
Klanderman, B	1
Gelb, AF	1
Taylor, CF	1
Simmons, M	1
Shinar, C	1
Kroegel, C	1
Valacer, DJ	1
Wu, X	1
Dev, A	1
Leong, AB	1
Jung, A	1
Kemp, JP	3
Snyder, L	1
Blanc, PD	1
Katz, PP	1
Yelin, EH	1
Eisner, MD	1
Ziboh, VA	1
Naguwa, S	1
Vang, K	1
Wineinger, J	1
Morrissey, BM	1
Watnik, M	1
Gershwin, ME	1
Leru, P	1
Dahlén, SE	2
Capra, V	1
Thompson, MD	1
Sala, A	1
Cole, DE	1
Folco, G	1
Rovati, GE	1
White, A	1
Ludington, E	1
Mehra, P	1
Stevenson, DD	2
Simon, RA	2
Scow, DT	1
Luttermoser, GK	1
Dickerson, KS	1
O'Connor, BJ	1
Löfdahl, CG	1
Balter, M	1
Szczeklik, A	2
Boulet, LP	1
Cairns, CB	2
Berger, W	2
De Chandt, MT	1
Wenzel, S	3
Busse, W	2
Calhoun, W	1
Panettieri, R	1
Peters-Golden, M	1
Dube, L	5
Walton-Bowen, K	3
Russell, H	1
Harris, J	1
Nelson, H	1
Kemp, J	1
Corren, J	1
Casale, T	1
LaVallee, N	1
Stepanians, M	1
Watkins, PB	1
Dube, LM	7
Cameron, CM	1
Kasten, LE	1
Snapper, JR	1
Brigham, KL	1
Fischer, AR	3
McFadden, CA	1
Frantz, R	1
Awni, WM	1
Cohn, J	6
Drazen, JM	9
Israel, E	7
Ado, VA	1
Mokronosova, MA	1
Perlamutrov, IuN	1
Wenzel, SE	3
Trudeau, JB	1
Kaminsky, DA	1
Martin, RJ	1
Westcott, JY	1
Ford-Hutchinson, AW	1
Rosenberg, MA	2
Lilly, CM	2
Callery, JC	2
Rubin, P	5
White, MV	1
Igarashi, Y	1
Kaliner, MA	1
Grossman, J	2
Pierson, W	1
Siegel, SC	1
Tinkelman, D	1
Murray, JJ	1
Segal, AT	1
Fish, J	1
Kaiser, HB	1
Ledford, D	1
Rosenthal, R	1
Lanni, C	3
Pearlman, H	1
Karahalios, P	1
Shapiro, J	1
Grimes, D	1
Sturm, RJ	1
Marinari, LR	1
Carlson, RP	1
Berkenkopf, JW	1
Musser, JH	1
Kreft, AF	1
Weichman, BM	1
McGill, KA	2
Busse, WW	2
Smith, LJ	1
Liu, MC	1
Lancaster, J	1
Tanaka, R	1
Larsen, JS	1
Jackson, SK	1
Van Schoor, J	1
Joos, GF	1
Kips, JC	1
Drajesk, JF	1
Carpentier, PJ	2
Pauwels, RA	1
Tan, RA	2
Spector, SL	2
Schwartz, HJ	1
Petty, T	1
Swanson, LJ	3
Lancaster, JF	3
Dekhuijzen, PN	1
Bootsma, GP	1
Wielders, PL	1
van den Berg, LR	1
Festen, J	1
van Herwaarden, CL	1
Dahlén, B	1
Nizankowska, E	1
Zetterström, O	1
Bochenek, G	1
Kumlin, M	1
Mastalerz, L	1
Pinis, G	1
Boodhoo, TI	1
Wright, S	1
Horwitz, RJ	1
Gómez, FP	1
Iglesia, R	1
Roca, J	1
Barberà, JA	1
Chung, KF	1
Rodriguez-Roisin, R	1
Drazen, J	2
Santais, MC	1
Callens, E	1
Djebbar, R	1
Ruff, F	1
Frieri, M	1
Therattil, JM	1
Zitt, M	1
Bouboulis, D	1
Wang, SF	1
Lark, G	1
Schaefer, PA	1
Sansone, G	1
Lane, SJ	1
Scuri, M	1
Allegra, L	1
Abraham, WM	2
DuBuske, LM	1
Lazarus, SC	1
Lee, T	1
Ochs, RF	1
Yandava, CN	1
Szczerback, N	1
Hippensteel, R	1
Pillari, A	1
Schork, N	1
Silverman, ES	1
Katz, DA	1
Drajesk, J	1
Kupczyk, M	1
Kuna, P	1
Hasday, JD	1
Meltzer, SS	1
Moore, WC	1
Wisniewski, P	1
Hebel, JR	1
Bleecker, ER	1
Dellaripa, PF	1
Wechsler, ME	1
Roth, ME	1
Lang, DM	1
Pauls, JD	1
Daffern, PJ	1
Bisgaard, H	1
Moy, ML	1
Juniper, EF	1
Krawiec, ME	1
García-Marcos, L	1
Schuster, A	1
Rimbrot, S	1
Bennett, M	1
Komorovski, M	1
Levy, Y	1
Reid, JJ	1
Minoguchi, K	1
Adachi, M	1
Hayden, ML	1
Ahmed, A	1
Cortes, A	1
Sielczak, MW	1
Hinz, W	1
Bouska, J	1
Bell, RL	1
O'Donnell, M	1
Payne, AN	2
Jackson, WP	1
Salmon, JA	1
Nicholls, A	1
Yeadon, M	1
Garland, LG	1
Hui, KP	1
Taylor, IK	1
Taylor, GW	1
Kesterson, J	1
Barnes, NC	1
Barnes, PJ	1
Bukantz, SC	1
Raub, W	1
Dermarkarian, R	1
Rosenberg, M	1
Sperling, R	1
Taylor, G	1